Introduction: Local Australian guidelines for the optimal management of stage III unresectable non-small cell lung cancer (NSCLC) are lacking. The American Society of Clinical Oncology (ASCO) guidelines recommend consolidation durvalumab for all patients with unresectable stage III NSCLC, irrespective of their PD-L1 expression or driver mutation status. The European Society of Medical Oncology (ESMO) differs, with consolidation durvalumab only recommended in those patients whose tumours express PD-L1. Methods: Due to differing global guidelines, we conducted an Australia and New Zealand wide survey of medical oncologists specialising in thoracic cancer to determine the variations in patterns of prescribing durvalumab in stage III unresectable NSCLC. This survey was done electronically and sponsored by the Thoracic Oncology Group of Australia (TOGA). Results: Thirty-two medical oncologists completed the survey. In patients with EGFR-mutated stage III unresectable NSCLC, 6% of respondents stated that they prescribed durvalumab for all patients, while an additional 6% strongly recommended treatment. Forty-four percent suggested little benefit of consolidation durvalumab in this cohort, with an additional 19% advocating for observation only. In patients with PD-L1 negative (0%) stage III unresectable NSCLC, 13% of respondents prescribed durvalumab for all patients, while an additional 56% strongly recommended treatment. Interestingly, 18%, 10%, and 10% of prescribers discussed self-funded oral tyrosine kinase inhibitor therapy in patients with EGFR, ALK, or ROS-1-mutated NSCLC respectively as a substitute for consolidation durvalumab. Conclusion: Overall, the clinical practice of Australian and New Zealand Medical Oncologists is variable, but remains consistent with either the ASCO or ESMO guidelines. Local practice guidelines are required to ensure consistency in prescribing patterns across Australia, as well as providing evidence for self-funded treatments outside standard of care.

1.
Wang
C-C
,
Chiu
L-C
,
Ju
J-S
,
Lin
Y-C
,
Fang
Y-F
,
Yang
C-T
,
.
Durvalumab as consolidation therapy in post-concurrent chemoradiation (CCRT) in unresectable stage III non-small cell lung cancer patients: a multicenter observational study
.
Vaccines
.
2021
;
9
(
10
):
1122
. .
2.
Parente
P
,
Chan
BA
,
Hughes
BGM
,
Jasas
K
,
Joshi
R
,
Kao
S
,
.
Patterns of care for stage III non–small cell lung cancer in Australia
.
Asia Pac J Clin Oncol
.
2019
;
15
(
3
):
93
100
. .
3.
Antonia
SJ
,
Villegas
A
,
Daniel
D
,
Vicente
D
,
Murakami
S
,
Hui
R
,
.
Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer
.
N Engl J Med
.
2017
;
377
(
20
):
1919
29
. .
4.
Spigel
DR
,
Faivre-Finn
C
,
Gray
JE
,
Vicente
D
,
Planchard
D
,
Paz-Ares
LG
,
.
Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: an update from the PACIFIC trial
.
J Clin Oncol
.
2021
;
39
(
15_Suppl l
):
8511
. .
5.
Naidoo
J
,
Antonia
S
,
Wu
YL
,
Cho
BC
,
Thiyagarajah
P
,
Mann
H
,
.
Brief report: durvalumab after chemoradiotherapy in unresectable stage III EGFR-mutant NSCLC: a post hoc subgroup analysis from PACIFIC
.
J Thorac Oncol
.
2023
;
18
(
5
):
657
63
. .
6.
Denault
M-H
,
Feng
J
,
Kuang
S
,
Shokoohi
A
,
Leung
B
,
Liu
M
,
.
Beyond PACIFIC: real-world outcomes of adjuvant durvalumab according to treatment received and PD-L1 expression
.
Curr Oncol
.
2023
;
30
(
8
):
7499
507
. .
7.
Daly
ME
,
Singh
N
,
Ismaila
N
,
Antonoff
MB
,
Arenberg
DA
,
Bradley
J
,
.
Management of stage III non–small-cell lung cancer: ASCO guideline
.
J Clin Oncol
.
2022
;
40
(
12
):
1356
84
. .
8.
Pentheroudakis
G
;
ESMO Guidelines Committee
.
Recent eUpdate to the ESMO Clinical Practice Guidelines on early and locally advanced non-small-cell lung cancer (NSCLC)
.
Ann Oncol
.
2020
;
31
(
9
):
1265
6
. .
9.
Aredo
JV
,
Mambetsariev
I
,
Hellyer
JA
,
Amini
A
,
Neal
JW
,
Padda
SK
,
.
Durvalumab for stage III EGFR-mutated NSCLC after definitive chemoradiotherapy
.
J Thorac Oncol
.
2021
;
16
(
6
):
1030
41
. .
10.
Nindra
U
,
Shahnam
A
,
Stevens
S
,
Pal
A
,
Nagrial
A
,
Lee
J
,
.
Influence of EGFR mutation status and PD-L1 expression in stage III unresectable non-small cell lung cancer treated with chemoradiation and consolidation durvalumab
.
Asia Pac J Clin Oncol
.
2023
. .
11.
Naidoo
J
,
Antonia
SJ
,
Wu
Y-L
,
Cho
BC
,
Thiyagarajah
P
,
Mann
H
,
.
Durvalumab (durva) after chemoradiotherapy (CRT) in unresectable, stage III, EGFR mutation-positive (EGFRm) NSCLC: a post hoc subgroup analysis from PACIFIC
.
J Clin Oncol
.
2022
;
40
(
16_Suppl l
):
8541
. .
12.
Lu
S
,
Casarini
I
,
Kato
T
,
Dols
MC
,
Özgüroğlu
M
,
Zeng
L
,
.
374TiP LAURA: osimertinib maintenance following definitive chemoradiation therapy (CRT) in patients (pts) with unresectable stage III epidermal growth factor receptor mutation positive (EGFRm) non-small cell lung cancer (NSCLC)
.
Ann Oncol
.
2020
;
31
:
S1385
. .
13.
Paz-Ares
L
,
Spira
A
,
Raben
D
,
Planchard
D
,
Cho
BC
,
Özgüroğlu
M
,
.
Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial
.
Ann Oncol
.
2020
;
31
(
6
):
798
806
. .
14.
Soria
J-C
,
Ohe
Y
,
Vansteenkiste
J
,
Reungwetwattana
T
,
Chewaskulyong
B
,
Lee
KH
,
.
Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer
.
N Engl J Med
.
2018
;
378
(
2
):
113
25
. .
15.
Diamond
BH
,
Belani
N
,
Masel
R
,
DeCarli
K
,
DiPetrillo
T
,
Hepel
JT
,
.
Predictors of pneumonitis in patients with locally advanced non-small cell lung cancer treated with definitive chemoradiation followed by consolidative durvalumab
.
Adv Radiat Oncol
.
2023
;
8
(
2
):
101130
. .
16.
Saez de Gordoa
K
,
Lopez
I
,
Marginet
M
,
Coloma
B
,
Frigola
G
,
Vega
N
,
.
PD-L1 expression in non-small cell lung cancer: data from a referral center in Spain
.
Diagnostics
.
2021
;
11
(
8
):
1452
. .
17.
Casal-Mouriño
A
,
Ruano-Ravina
A
,
Lorenzo-González
M
,
Rodríguez-Martínez
Á
,
Giraldo-Osorio
A
,
Varela-Lema
L
,
.
Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival
.
Transl Lung Cancer Res
.
2021
;
10
(
1
):
506
18
. .
You do not currently have access to this content.